Calgary, Alberta — November 18, 2025 — Leads & Copy —Resverlogix Corp. (TSX: RVX) has appointed Mr. Bradley Glass, J.D., to its board of directors, effective today.
Mr. Glass brings extensive legal and business experience to Resverlogix. For the past four years, he has served as General Counsel of Hepalink USA, Inc. and its subsidiaries (“Hepalink”), where he manages all of Hepalink’s U.S. legal issues. Before joining Hepalink, Mr. Glass spent over 20 years in private law practice, advising clients across the United States on a wide range of matters. He has litigated numerous cases in federal, state, and local courts and administrative tribunals, focusing on complex business and regulatory matters.
Mr. Glass is a graduate of Wabash College and the Indiana University School of Law.
“We are very pleased to welcome Bradley Glass to Resverlogix’s board of directors,” said Donald McCaffrey, Chairman and CEO. “Bradley’s decades of legal and business experience will bring a valuable perspective to our Board. We look forward to Bradley’s insights and contributions in advancing our strategic objectives.”
Mr. Glass stated he is “thrilled to join the board and look forward to supporting Resverlogix’s progress,” adding that the appointment reflects the “common goal of apabetalone’s successful development” between Resverlogix and Hepalink.
Resverlogix, founded in 2001 and based in Calgary, is a late-stage biotechnology company focused on epigenetics. It aims to develop therapies for patients with chronic diseases. The Company’s clinical program evaluates its lead epigenetic candidate, apabetalone, for the treatment of cardiovascular disease, associated comorbidities, and post COVID-19 conditions.
Resverlogix has partnered with EVERSANA™, a commercial services provider to the life sciences industry, to support the rapid commercialization of apabetalone in Canada and the United States for cardiovascular disease, post COVID-19 conditions, and pulmonary arterial hypertension.
Resverlogix common shares are traded on the Toronto Stock Exchange under the symbol TSX: RVX.
Investor Relations
Email: ir@resverlogix.com
Phone: 403-254-9252
Source: Resverlogix Corp.
